Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):868–870. doi: 10.1038/bjc.1990.397

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.

A R Dixon 1, J F Robertson 1, L Jackson 1, R I Nicholson 1, K J Walker 1, R W Blamey 1
PMCID: PMC1971509  PMID: 2147110

Abstract

In premenopausal women with advanced breast cancer the luteinising hormone-releasing hormone agonist goserelin (Zoladex, ICI plc) will produce serum levels of oestradiol equivalent to those following surgical oophorectomy or the menopause. This paper reports our further experience of using this drug in 75 premenopausal patients with advanced breast cancer. In addition to response rates, duration of response is reported. An objective response was seen in 25 patients (33%), the median duration of which was in excess of 15 months. Seven patients (9%) showed a complete response to therapy; median duration greater than 37 months. There was no significant difference in time to disease progression (Lee-Desu statistic 18.26, 1 d.f., P = 0.43) and probability of survival (Lee-Desu statistic 3.41, 1 d.f., P = 0.07) between those patients assessed as having either static disease, or those showing a partial response at six months. Response to therapy correlates significantly with the oestrogen receptor status of the primary tumour (X2 = 20.59, 6 d.f., P less than 0.005). The modest side-effects, ease of administration and reversibility make this approach to therapy very attractive. This is to be remembered in that 53% of patients had disease progression whilst receiving goserelin. These patients thus avoided the unnecessary and irreversible morbidity associated with surgical oophorectomy. With the proven efficacy and minimal morbidity associated with goserelin we believe there is no current role for surgical oophorectomy in the management of premenopausal patients with advanced breast cancer.

Full text

PDF
868

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beksaç M. S., Kişnişci H. A., Cakar A. N., Beksaç M. The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. Int J Fertil. 1983;28(4):219–224. [PubMed] [Google Scholar]
  2. Buchanan R. B., Blamey R. W., Durrant K. R., Howell A., Paterson A. G., Preece P. E., Smith D. C., Williams C. J., Wilson R. G. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326–1330. doi: 10.1200/JCO.1986.4.9.1326. [DOI] [PubMed] [Google Scholar]
  3. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  4. KENNEDY B. J., MIELKE P. W., Jr, FORTUNY I. E. THERAPEUTIC CASTRATION VERSUS PROPHYLACTIC CASTRATION IN BREAST CANCER. Surg Gynecol Obstet. 1964 Mar;118:524–540. [PubMed] [Google Scholar]
  5. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  6. Nicholson R. I., Campbell F. C., Blamey R. W., Elston C. W., George D., Griffiths K. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981 Dec;15:193–199. doi: 10.1016/0022-4731(81)90275-2. [DOI] [PubMed] [Google Scholar]
  7. Nicholson R. I., Walker K. J., Turkes A., Dyas J., Plowman P. N., Williams M., Blamey R. W. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem. 1985 Nov;23(5B):843–847. doi: 10.1016/s0022-4731(85)80025-x. [DOI] [PubMed] [Google Scholar]
  8. Nicholson R. I., Walker K. J., Turkes A., Turkes A. O., Dyas J., Blamey R. W., Campbell F. C., Robinson M. R., Griffiths K. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. J Steroid Biochem. 1984 Jan;20(1):129–135. doi: 10.1016/0022-4731(84)90199-7. [DOI] [PubMed] [Google Scholar]
  9. Robertson J. F., Walker K. J., Nicholson R. I., Blamey R. W. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br J Surg. 1989 Dec;76(12):1262–1265. doi: 10.1002/bjs.1800761213. [DOI] [PubMed] [Google Scholar]
  10. Robertson J. F., Williams M. R., Todd J., Nicholson R. I., Morgan D. A., Blamey R. W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol. 1989 Mar;25(3):469–475. doi: 10.1016/0277-5379(89)90259-9. [DOI] [PubMed] [Google Scholar]
  11. Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab. 1976 Feb;42(2):247–253. doi: 10.1210/jcem-42-2-247. [DOI] [PubMed] [Google Scholar]
  12. Walker K. J., Turkes A., Williams M. R., Blamey R. W., Nicholson R. I. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. J Endocrinol. 1986 Nov;111(2):349–353. doi: 10.1677/joe.0.1110349. [DOI] [PubMed] [Google Scholar]
  13. Walker K. J., Walker R. F., Turkes A., Robertson J. F., Blamey R. W., Griffiths K., Nicholson R. I. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol. 1989 Apr;25(4):651–654. doi: 10.1016/0277-5379(89)90200-9. [DOI] [PubMed] [Google Scholar]
  14. Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES